当前位置: X-MOL 学术J. Radioanal. Nucl. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Synthesis of deuterium-labeled nelarabine and its active ingredient, ara-G
Journal of Radioanalytical and Nuclear Chemistry ( IF 1.5 ) Pub Date : 2020-05-12 , DOI: 10.1007/s10967-020-07193-7
Damin Zhao , Jing Ren , Qinglin Wang , Yinsheng Zhang

Nelarabine is a prodrug of the deoxyguanosine analogue, 9-β-D-arabinofuranose guanine (ara-G), which is used for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). For the clinical study of nelarabine and its active ingredient, ara-G, a suitable isotope-labeled internal standard was required. Effective and operationally simple methods for the synthesis of [D 4 ]]nelarabine and [D 3 ]ara-G were developed with high deuterium incorporation using D 2 O, CD 3 OD and NaBD 4 as deuterium sources. It was found that [D 3 ]ara-G was useful as an internal standard instead of [D 4 ]nelarabine. Graphic abstract Nelarabine is a prodrug of the deoxyguanosine analogue, 9-β-D-arabinofurose guanine (ara-G), which is used for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). For the clinical study of nelarabine and its active ingredient, ara-G, a suitable isotope-labeled internal was not suitable as an internalstandard was required. Effective and operationally simple methods for the synthesis of [D 4 ]]nelarabine and [D 3 ]ara-G were developed with high deuterium incorporation using D 2 O, CD 3 OD and NaBD 4 as deuterium sources. It was found that [D 3 ]ara-G was useful as an internal standard instead of [D 4 ]nelarabine.

中文翻译:

氘标记奈拉滨及其活性成分ara-G的合成

奈拉滨是脱氧鸟苷类似物 9-β-D-阿拉伯呋喃糖鸟嘌呤 (ara-G) 的前药,用于治疗 T 细胞急性淋巴细胞白血病 (T-ALL) 和 T 细胞淋巴母细胞淋巴瘤。 T-LBL)。对于奈拉滨及其活性成分 ara-G 的临床研究,需要合适的同位素标记内标。使用 D 2 O、CD 3 OD 和 NaBD 4 作为氘源,开发了合成 [D 4 ]]奈拉滨和 [D 3 ]ara-G 的有效且操作简单的方法,其中氘掺入率高。发现[D 3 ]ara-G代替[D 4 ]奈拉滨可用作内标。图形摘要奈拉滨是脱氧鸟苷类似物 9-β-D-阿拉伯呋喃鸟嘌呤 (ara-G) 的前药,用于治疗 T 细胞急性淋巴细胞白血病 (T-ALL) 和 T 细胞淋巴细胞淋巴瘤 (T-LBL) 患者。对于奈拉滨及其活性成分 ara-G 的临床研究,由于需要合适的同位素标记内标,因此不合适。使用 D 2 O、CD 3 OD 和 NaBD 4 作为氘源,开发了合成 [D 4 ]]奈拉滨和 [D 3 ]ara-G 的有效且操作简单的方法,其中氘掺入率高。发现[D 3 ]ara-G代替[D 4 ]奈拉滨可用作内标。使用 D 2 O、CD 3 OD 和 NaBD 4 作为氘源,开发了合成 [D 4 ]]奈拉滨和 [D 3 ]ara-G 的有效且操作简单的方法,其中氘掺入率高。发现[D 3 ]ara-G代替[D 4 ]奈拉滨可用作内标。使用 D 2 O、CD 3 OD 和 NaBD 4 作为氘源,开发了合成 [D 4 ]]奈拉滨和 [D 3 ]ara-G 的有效且操作简单的方法,其中氘掺入率高。发现[D 3 ]ara-G代替[D 4 ]奈拉滨可用作内标。
更新日期:2020-05-12
down
wechat
bug